This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Ketanserin
Accession Number
DB12465
Type
Small Molecule
Groups
Investigational
Description

Ketanserin has been investigated for the treatment of Septic Shock, Severe Sepsis, and Diabetic Foot Ulcer.

Structure
Thumb
Synonyms
Not Available
External IDs
R-41,468 / R-41468
Categories
UNII
97F9DE4CT4
CAS number
74050-98-9
Weight
Average: 395.434
Monoisotopic: 395.164519743
Chemical Formula
C22H22FN3O3
InChI Key
FPCCSQOGAWCVBH-UHFFFAOYSA-N
InChI
InChI=1S/C22H22FN3O3/c23-17-7-5-15(6-8-17)20(27)16-9-11-25(12-10-16)13-14-26-21(28)18-3-1-2-4-19(18)24-22(26)29/h1-8,16H,9-14H2,(H,24,29)
IUPAC Name
3-{2-[4-(4-fluorobenzoyl)piperidin-1-yl]ethyl}-1,2,3,4-tetrahydroquinazoline-2,4-dione
SMILES
FC1=CC=C(C=C1)C(=O)C1CCN(CCN2C(=O)NC3=CC=CC=C3C2=O)CC1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
U5-hydroxytryptamine receptor 2A
inverse agonist
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Ketanserin.Experimental
AbciximabKetanserin may increase the anticoagulant activities of Abciximab.Approved
AcebutololKetanserin may increase the hypotensive activities of Acebutolol.Approved, Investigational
AcemetacinThe therapeutic efficacy of Ketanserin can be decreased when used in combination with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolKetanserin may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Ketanserin is combined with Acetylsalicylic acid.Approved, Vet Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Ketanserin.Approved, Investigational
AliskirenKetanserin may increase the hypotensive activities of Aliskiren.Approved, Investigational
AloxiprinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Aloxiprin.Experimental
AlprenololKetanserin may increase the hypotensive activities of Alprenolol.Approved, Withdrawn
AlprostadilAlprostadil may increase the antiplatelet activities of Ketanserin.Approved, Investigational
AlteplaseKetanserin may increase the anticoagulant activities of Alteplase.Approved
AmbrisentanKetanserin may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmifostineKetanserin may increase the hypotensive activities of Amifostine.Approved, Investigational
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Ketanserin is combined with Aminosalicylic Acid.Approved
AmlodipineKetanserin may increase the hypotensive activities of Amlodipine.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Ketanserin.Approved, Illicit, Investigational
AnagrelideKetanserin may increase the anticoagulant activities of Anagrelide.Approved
AncrodKetanserin may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the antiplatelet activities of Ketanserin.Investigational
AnistreplaseKetanserin may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanKetanserin may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Ketanserin is combined with Apixaban.Approved
ArdeparinKetanserin may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanKetanserin may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinKetanserin may increase the anticoagulant activities of Astaxanthin.Investigational
AtenololKetanserin may increase the hypotensive activities of Atenolol.Approved
AvanafilAvanafil may increase the antihypertensive activities of Ketanserin.Approved
AzelastineAzelastine may increase the antiplatelet activities of Ketanserin.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Ketanserin is combined with Balsalazide.Approved, Investigational
BarnidipineKetanserin may increase the antihypertensive activities of Barnidipine.Approved
BatroxobinKetanserin may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminKetanserin may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinKetanserin may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BenazeprilKetanserin may increase the hypotensive activities of Benazepril.Approved, Investigational
BendroflumethiazideKetanserin may increase the hypotensive activities of Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Ketanserin.Withdrawn
BepridilKetanserin may increase the hypotensive activities of Bepridil.Approved, Withdrawn
BeraprostKetanserin may increase the anticoagulant activities of Beraprost.Investigational
BetaxololKetanserin may increase the hypotensive activities of Betaxolol.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Ketanserin.Approved
BietaserpineKetanserin may increase the hypotensive activities of Bietaserpine.Experimental
BimatoprostKetanserin may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BisoprololKetanserin may increase the hypotensive activities of Bisoprolol.Approved
BivalirudinKetanserin may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Ketanserin.Approved, Investigational
BQ-123Ketanserin may increase the hypotensive activities of BQ-123.Investigational
BretyliumKetanserin may increase the hypotensive activities of Bretylium.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Ketanserin.Approved
BrinaseKetanserin may increase the anticoagulant activities of Brinase.Experimental
BrofaromineBrofaromine may increase the hypotensive activities of Ketanserin.Experimental
BuflomedilKetanserin may increase the antiplatelet activities of Buflomedil.Experimental
BupranololKetanserin may increase the hypotensive activities of Bupranolol.Approved
BupropionThe risk or severity of adverse effects can be increased when Bupropion is combined with Ketanserin.Approved
ButylphthalideKetanserin may increase the antiplatelet activities of Butylphthalide.Investigational
CadralazineKetanserin may increase the hypotensive activities of Cadralazine.Experimental
CafedrineKetanserin may increase the hypotensive activities of Cafedrine.Investigational
CandesartanKetanserin may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilKetanserin may increase the hypotensive activities of Candesartan cilexetil.Approved
CandoxatrilKetanserin may increase the hypotensive activities of Candoxatril.Experimental
CangrelorKetanserin may increase the anticoagulant activities of Cangrelor.Approved
CaplacizumabKetanserin may increase the anticoagulant activities of Caplacizumab.Investigational
CaptoprilKetanserin may increase the hypotensive activities of Captopril.Approved
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Ketanserin is combined with Carbaspirin calcium.Experimental, Investigational
CaroxazoneCaroxazone may increase the hypotensive activities of Ketanserin.Withdrawn
CarteololKetanserin may increase the hypotensive activities of Carteolol.Approved
CarvedilolKetanserin may increase the hypotensive activities of Carvedilol.Approved, Investigational
CeliprololKetanserin may increase the hypotensive activities of Celiprolol.Approved, Investigational
CertoparinKetanserin may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChlorothiazideKetanserin may increase the hypotensive activities of Chlorothiazide.Approved, Vet Approved
ChlorthalidoneKetanserin may increase the hypotensive activities of Chlorthalidone.Approved
CicletanineKetanserin may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilKetanserin may increase the hypotensive activities of Cilazapril.Approved
CilostazolKetanserin may increase the anticoagulant activities of Cilostazol.Approved, Investigational
Citric AcidKetanserin may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Ketanserin.Approved
ClopidogrelKetanserin may increase the anticoagulant activities of Clopidogrel.Approved
CloranololKetanserin may increase the hypotensive activities of Cloranolol.Experimental
CloricromenKetanserin may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneKetanserin may increase the anticoagulant activities of Clorindione.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Ketanserin is combined with Collagenase clostridium histolyticum.Approved, Investigational
CryptenamineKetanserin may increase the hypotensive activities of Cryptenamine.Approved
CyclopenthiazideKetanserin may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclothiazideKetanserin may increase the hypotensive activities of Cyclothiazide.Approved
Dabigatran etexilateKetanserin may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinKetanserin may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidKetanserin may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanKetanserin may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Ketanserin.Approved, Investigational
DebrisoquinDebrisoquin may increase the hypotensive activities of Ketanserin.Approved, Investigational
DefibrotideKetanserin may increase the anticoagulant activities of Defibrotide.Approved, Investigational
DelaprilKetanserin may increase the hypotensive activities of Delapril.Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Ketanserin is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Ketanserin is combined with Dersalazine.Investigational
DeserpidineKetanserin may increase the hypotensive activities of Deserpidine.Approved
DesirudinKetanserin may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseKetanserin may increase the anticoagulant activities of Desmoteplase.Investigational
DesvenlafaxineDesvenlafaxine may increase the antiplatelet activities of Ketanserin.Approved, Investigational
DextranKetanserin may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DiazoxideDiazoxide may increase the hypotensive activities of Ketanserin.Approved
DicoumarolKetanserin may increase the anticoagulant activities of Dicoumarol.Approved
DiethylnorspermineKetanserin may increase the hypotensive activities of Diethylnorspermine.Investigational
DiflunisalThe risk or severity of adverse effects can be increased when Ketanserin is combined with Diflunisal.Approved, Investigational
DihydralazineKetanserin may increase the hypotensive activities of Dihydralazine.Approved, Investigational
DiltiazemKetanserin may increase the hypotensive activities of Diltiazem.Approved, Investigational
DiphenadioneKetanserin may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleKetanserin may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleKetanserin may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
DorzolamideKetanserin may increase the hypotensive activities of Dorzolamide.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Ketanserin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketanserin.Approved, Vet Approved
Drotrecogin alfaKetanserin may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidKetanserin may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanKetanserin may increase the anticoagulant activities of Edoxaban.Approved
EfonidipineKetanserin may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilKetanserin may increase the hypotensive activities of Enalapril.Approved, Vet Approved
EnalaprilatKetanserin may increase the hypotensive activities of Enalaprilat.Approved
EndralazineKetanserin may increase the hypotensive activities of Endralazine.Experimental
EnoxaparinKetanserin may increase the anticoagulant activities of Enoxaparin.Approved
EpanololKetanserin may increase the hypotensive activities of Epanolol.Experimental
EpinastineEpinastine may increase the antiplatelet activities of Ketanserin.Approved, Investigational
EplivanserinKetanserin may increase the anticoagulant activities of Eplivanserin.Investigational
EpoprostenolKetanserin may increase the anticoagulant activities of Epoprostenol.Approved
EprosartanKetanserin may increase the hypotensive activities of Eprosartan.Approved
EptifibatideKetanserin may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
EthanolKetanserin may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
Ethyl biscoumacetateKetanserin may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
FelodipineKetanserin may increase the hypotensive activities of Felodipine.Approved, Investigational
FenoldopamKetanserin may increase the hypotensive activities of Fenoldopam.Approved
Ferulic acidKetanserin may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinKetanserin may increase the anticoagulant activities of Fibrinolysin.Investigational
FluindioneKetanserin may increase the anticoagulant activities of Fluindione.Approved, Investigational
FluoxetineFluoxetine may increase the antiplatelet activities of Ketanserin.Approved, Vet Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Ketanserin.Approved
FondaparinuxKetanserin may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
FosinoprilKetanserin may increase the hypotensive activities of Fosinopril.Approved
FostamatinibFostamatinib may increase the antihypertensive activities of Ketanserin.Approved, Investigational
FurazolidoneFurazolidone may increase the hypotensive activities of Ketanserin.Approved, Investigational, Vet Approved
GabexateKetanserin may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Ketanserin.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Ketanserin is combined with Guacetisal.Experimental
GuanabenzKetanserin may increase the hypotensive activities of Guanabenz.Approved, Investigational
GuanadrelKetanserin may increase the hypotensive activities of Guanadrel.Approved
GuanazodineKetanserin may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineKetanserin may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Ketanserin.Approved, Investigational
GuanoclorKetanserin may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzKetanserin may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanKetanserin may increase the hypotensive activities of Guanoxan.Experimental
HarmalineHarmaline may increase the hypotensive activities of Ketanserin.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Ketanserin is combined with Hemoglobin crosfumaril.Experimental
HeparinKetanserin may increase the anticoagulant activities of Heparin.Approved, Investigational
HexamethoniumKetanserin may increase the hypotensive activities of Hexamethonium.Experimental
HigenamineKetanserin may increase the anticoagulant activities of Higenamine.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Ketanserin.Experimental
HydralazineHydralazine may increase the hypotensive activities of Ketanserin.Approved
HydrochlorothiazideKetanserin may increase the hypotensive activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideKetanserin may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydroxytyrosolKetanserin may increase the antiplatelet activities of Hydroxytyrosol.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ketanserin is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ketanserin.Approved
IbudilastIbudilast may increase the antiplatelet activities of Ketanserin.Approved, Investigational
IbuprofenThe therapeutic efficacy of Ketanserin can be decreased when used in combination with Ibuprofen.Approved
Icosapent ethylIcosapent ethyl may increase the antiplatelet activities of Ketanserin.Approved, Investigational, Nutraceutical
IdraparinuxKetanserin may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the antiplatelet activities of Ketanserin.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the antiplatelet activities of Ketanserin.Investigational
IloprostKetanserin may increase the anticoagulant activities of Iloprost.Approved, Investigational
ImidaprilKetanserin may increase the hypotensive activities of Imidapril.Investigational
IndapamideKetanserin may increase the hypotensive activities of Indapamide.Approved
IndenololKetanserin may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenKetanserin may increase the anticoagulant activities of Indobufen.Investigational
IndoraminIndoramin may increase the hypotensive activities of Ketanserin.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Ketanserin.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Ketanserin.Withdrawn
IrbesartanKetanserin may increase the hypotensive activities of Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Ketanserin.Approved
IsradipineKetanserin may increase the hypotensive activities of Isradipine.Approved, Investigational
LabetalolKetanserin may increase the hypotensive activities of Labetalol.Approved
LacidipineKetanserin may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Ketanserin.Approved, Investigational
LatanoprostKetanserin may increase the hypotensive activities of Latanoprost.Approved, Investigational
LepirudinKetanserin may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineKetanserin may increase the hypotensive activities of Lercanidipine.Approved, Investigational
LetaxabanKetanserin may increase the anticoagulant activities of Letaxaban.Investigational
LimaprostLimaprost may increase the antiplatelet activities of Ketanserin.Approved, Investigational
LinsidomineKetanserin may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilKetanserin may increase the hypotensive activities of Lisinopril.Approved, Investigational
LofexidineKetanserin may increase the hypotensive activities of Lofexidine.Approved, Investigational
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Ketanserin.Approved, Investigational
LosartanKetanserin may increase the hypotensive activities of Losartan.Approved
MacitentanKetanserin may increase the hypotensive activities of Macitentan.Approved
Magnesium carbonateThe risk or severity of adverse effects can be increased when Magnesium carbonate is combined with Ketanserin.Approved, Investigational
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when Magnesium Trisilicate is combined with Ketanserin.Approved
ManidipineKetanserin may increase the hypotensive activities of Manidipine.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Ketanserin.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Ketanserin.Approved, Investigational
MelagatranKetanserin may increase the anticoagulant activities of Melagatran.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Ketanserin is combined with Mesalazine.Approved
MethoserpidineKetanserin may increase the hypotensive activities of Methoserpidine.Experimental
Methyl salicylateThe risk or severity of adverse effects can be increased when Ketanserin is combined with Methyl salicylate.Approved, Vet Approved
MethyldopaKetanserin may increase the hypotensive activities of Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Ketanserin.Approved, Investigational
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Ketanserin.Approved, Investigational
MetipranololKetanserin may increase the hypotensive activities of Metipranolol.Approved
MetolazoneKetanserin may increase the hypotensive activities of Metolazone.Approved
MetoprololKetanserin may increase the hypotensive activities of Metoprolol.Approved, Investigational
MetyrosineKetanserin may increase the hypotensive activities of Metyrosine.Approved
MibefradilKetanserin may increase the hypotensive activities of Mibefradil.Investigational, Withdrawn
MilrinoneMilrinone may increase the antiplatelet activities of Ketanserin.Approved
MinaprineMinaprine may increase the hypotensive activities of Ketanserin.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Ketanserin.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Ketanserin.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Ketanserin.Approved, Investigational
MoexiprilKetanserin may increase the hypotensive activities of Moexipril.Approved
MolsidomineMolsidomine may increase the hypotensive activities of Ketanserin.Approved, Investigational
MoxonidineMoxonidine may increase the hypotensive activities of Ketanserin.Approved, Investigational
MuzolimineKetanserin may increase the hypotensive activities of Muzolimine.Experimental
NadololKetanserin may increase the hypotensive activities of Nadolol.Approved
NadroparinKetanserin may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatKetanserin may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilKetanserin may increase the hypotensive activities of Naftopidil.Investigational
NebivololKetanserin may increase the hypotensive activities of Nebivolol.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Ketanserin.Withdrawn
NicardipineKetanserin may increase the hypotensive activities of Nicardipine.Approved, Investigational
NicorandilKetanserin may increase the hypotensive activities of Nicorandil.Approved, Investigational
NiguldipineKetanserin may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineKetanserin may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideNimesulide may increase the antiplatelet activities of Ketanserin.Approved, Investigational, Withdrawn
NimodipineKetanserin may increase the hypotensive activities of Nimodipine.Approved, Investigational
NisoldipineKetanserin may increase the hypotensive activities of Nisoldipine.Approved
NitrendipineKetanserin may increase the hypotensive activities of Nitrendipine.Approved, Investigational
NitroaspirinThe risk or severity of adverse effects can be increased when Ketanserin is combined with Nitroaspirin.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Ketanserin.Approved, Investigational
ObinutuzumabKetanserin may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Ketanserin.Withdrawn
OlmesartanKetanserin may increase the hypotensive activities of Olmesartan.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Ketanserin is combined with Olsalazine.Approved
OmapatrilatKetanserin may increase the hypotensive activities of Omapatrilat.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Ketanserin.Approved, Nutraceutical
OtamixabanKetanserin may increase the anticoagulant activities of Otamixaban.Investigational
OxprenololKetanserin may increase the hypotensive activities of Oxprenolol.Approved
OzagrelKetanserin may increase the anticoagulant activities of Ozagrel.Investigational
PargylinePargyline may increase the hypotensive activities of Ketanserin.Approved
ParnaparinKetanserin may increase the anticoagulant activities of Parnaparin.Approved, Investigational
PenbutololKetanserin may increase the hypotensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateKetanserin may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentoliniumKetanserin may increase the hypotensive activities of Pentolinium.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ketanserin.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Ketanserin.Approved, Investigational
PerindoprilKetanserin may increase the hypotensive activities of Perindopril.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Ketanserin.Approved
PhenindioneKetanserin may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the hypotensive activities of Ketanserin.Withdrawn
PhenoxybenzamineKetanserin may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Ketanserin.Withdrawn
PhenprocoumonKetanserin may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentolamineKetanserin may increase the hypotensive activities of Phentolamine.Approved
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Ketanserin is combined with Phenyl aminosalicylate.Approved
PicotamideKetanserin may increase the anticoagulant activities of Picotamide.Experimental
PinacidilPinacidil may increase the hypotensive activities of Ketanserin.Approved
PindololKetanserin may increase the hypotensive activities of Pindolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Ketanserin.Approved
PivhydrazinePivhydrazine may increase the hypotensive activities of Ketanserin.Withdrawn
Platelet Activating FactorKetanserin may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideKetanserin may increase the hypotensive activities of Polythiazide.Approved
Potassium CitrateKetanserin may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PrasugrelKetanserin may increase the anticoagulant activities of Prasugrel.Approved
PrazosinPrazosin may increase the hypotensive activities of Ketanserin.Approved
ProcaineProcaine may increase the hypotensive activities of Ketanserin.Approved, Investigational, Vet Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Ketanserin.Approved, Investigational
PropranololKetanserin may increase the hypotensive activities of Propranolol.Approved, Investigational
Protein CKetanserin may increase the anticoagulant activities of Protein C.Approved
Protein S humanKetanserin may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeKetanserin may increase the anticoagulant activities of Protocatechualdehyde.Approved
PseudoephedrineThe risk or severity of adverse effects can be increased when Ketanserin is combined with Pseudoephedrine.Approved
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ketanserin.Approved
QuinaprilKetanserin may increase the hypotensive activities of Quinapril.Approved, Investigational
QuinineQuinine may increase the hypotensive activities of Ketanserin.Approved
RamatrobanKetanserin may increase the antiplatelet activities of Ramatroban.Investigational
RamiprilKetanserin may increase the hypotensive activities of Ramipril.Approved
RasagilineRasagiline may increase the hypotensive activities of Ketanserin.Approved
RelcovaptanKetanserin may increase the antiplatelet activities of Relcovaptan.Investigational
RemikirenKetanserin may increase the hypotensive activities of Remikiren.Approved
RescinnamineKetanserin may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Ketanserin.Approved, Investigational
ResveratrolResveratrol may increase the antiplatelet activities of Ketanserin.Approved, Experimental, Investigational
ReteplaseKetanserin may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinKetanserin may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the antiplatelet activities of Ketanserin.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Ketanserin.Approved, Investigational
RiociguatKetanserin may increase the hypotensive activities of Riociguat.Approved
RituximabKetanserin may increase the hypotensive activities of Rituximab.Approved
RivaroxabanKetanserin may increase the anticoagulant activities of Rivaroxaban.Approved
SafrazineSafrazine may increase the hypotensive activities of Ketanserin.Withdrawn
Salicylic acidThe risk or severity of adverse effects can be increased when Ketanserin is combined with Salicylic acid.Approved, Investigational, Vet Approved
SaprisartanKetanserin may increase the hypotensive activities of Saprisartan.Experimental
SarpogrelateKetanserin may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseKetanserin may increase the anticoagulant activities of Saruplase.Experimental
SelegilineSelegiline may increase the hypotensive activities of Ketanserin.Approved, Investigational, Vet Approved
SelexipagKetanserin may increase the anticoagulant activities of Selexipag.Approved
SevofluraneSevoflurane may increase the antiplatelet activities of Ketanserin.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Ketanserin.Approved, Investigational
SitaxentanKetanserin may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium CitrateKetanserin may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
SpiraprilKetanserin may increase the hypotensive activities of Spirapril.Approved
SRT501SRT501 may increase the antiplatelet activities of Ketanserin.Investigational
StreptokinaseKetanserin may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulodexideKetanserin may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Ketanserin.Approved, Investigational
TalinololKetanserin may increase the hypotensive activities of Talinolol.Investigational
TelmisartanKetanserin may increase the hypotensive activities of Telmisartan.Approved, Investigational
TemocaprilKetanserin may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenecteplaseKetanserin may increase the anticoagulant activities of Tenecteplase.Approved
TerlipressinKetanserin may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneTesmilifene may increase the antiplatelet activities of Ketanserin.Investigational
TetrahydropalmatineKetanserin may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineKetanserin may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineTheophylline may increase the antihypertensive activities of Ketanserin.Approved
TiboloneKetanserin may increase the hypotensive activities of Tibolone.Approved, Investigational
TicagrelorKetanserin may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineKetanserin may increase the anticoagulant activities of Ticlopidine.Approved
TicrynafenKetanserin may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololKetanserin may increase the hypotensive activities of Timolol.Approved
TinzaparinKetanserin may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolKetanserin may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Ketanserin.Approved, Investigational
TirofibanKetanserin may increase the anticoagulant activities of Tirofiban.Approved
TolazolineKetanserin may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolonidineKetanserin may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Ketanserin.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Ketanserin.Approved
TorasemideKetanserin may increase the hypotensive activities of Torasemide.Approved
TositumomabThe risk or severity of adverse effects can be increased when Ketanserin is combined with Tositumomab.Approved, Investigational
TrandolaprilKetanserin may increase the hypotensive activities of Trandolapril.Approved
TranilastTranilast may increase the antiplatelet activities of Ketanserin.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Ketanserin.Approved, Investigational
TrapidilTrapidil may increase the antiplatelet activities of Ketanserin.Approved
TravoprostKetanserin may increase the hypotensive activities of Travoprost.Approved
TreprostinilKetanserin may increase the anticoagulant activities of Treprostinil.Approved, Investigational
TrichlormethiazideKetanserin may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TriflusalKetanserin may increase the anticoagulant activities of Triflusal.Approved, Investigational
TrimazosinTrimazosin may increase the hypotensive activities of Ketanserin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Ketanserin.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Ketanserin is combined with Trolamine salicylate.Approved
TroxerutinKetanserin may increase the anticoagulant activities of Troxerutin.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Ketanserin.Approved, Investigational
UnoprostoneKetanserin may increase the hypotensive activities of Unoprostone.Approved, Investigational
UrapidilKetanserin may increase the hypotensive activities of Urapidil.Investigational
UrokinaseKetanserin may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
ValsartanKetanserin may increase the hypotensive activities of Valsartan.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Ketanserin.Approved
VenlafaxineVenlafaxine may increase the antiplatelet activities of Ketanserin.Approved
VincamineKetanserin may increase the hypotensive activities of Vincamine.Experimental
VinpocetineKetanserin may increase the hypotensive activities of Vinpocetine.Investigational
Vitamin EVitamin E may increase the antiplatelet activities of Ketanserin.Approved, Nutraceutical, Vet Approved
VorapaxarKetanserin may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinKetanserin may increase the anticoagulant activities of Warfarin.Approved
XimelagatranKetanserin may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XipamideKetanserin may increase the hypotensive activities of Xipamide.Experimental
XylometazolineKetanserin may increase the hypotensive activities of Xylometazoline.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Ketanserin.Approved, Investigational, Vet Approved
ZofenoprilKetanserin may increase the hypotensive activities of Zofenopril.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
KEGG Compound
C07464
PubChem Compound
3822
PubChem Substance
347828704
ChemSpider
3690
BindingDB
21395
ChEBI
6123
ChEMBL
CHEMBL51
Wikipedia
Ketanserin
ATC Codes
C02KD01 — Ketanserin

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1RecruitingBasic ScienceBasic Science1
1, 2CompletedTreatmentDiabetic Foot Ulcers (DFU)1
3CompletedTreatmentSevere Sepsis / Shock, Septic1
3TerminatedPreventionAcute Renal Failure (ARF)1
Not AvailableCompletedBasic ScienceHealthy Volunteers1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.156 mg/mLALOGPS
logP2.92ALOGPS
logP3.61ChemAxon
logS-3.4ALOGPS
pKa (Strongest Acidic)11.42ChemAxon
pKa (Strongest Basic)7.29ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area69.72 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity109.11 m3·mol-1ChemAxon
Polarizability39.89 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as alkyl-phenylketones. These are aromatic compounds containing a ketone substituted by one alkyl group, and a phenyl group.
Kingdom
Organic compounds
Super Class
Organic oxygen compounds
Class
Organooxygen compounds
Sub Class
Carbonyl compounds
Direct Parent
Alkyl-phenylketones
Alternative Parents
Quinazolines / Aryl alkyl ketones / Benzoyl derivatives / Pyrimidones / Fluorobenzenes / Hydroxypyrimidines / Gamma-amino ketones / Aryl fluorides / Piperidines / Heteroaromatic compounds
show 7 more
Substituents
Alkyl-phenylketone / Diazanaphthalene / Quinazoline / Benzoyl / Aryl alkyl ketone / Fluorobenzene / Halobenzene / Hydroxypyrimidine / Pyrimidone / Aryl fluoride
show 21 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
piperidines, organofluorine compound, aromatic ketone, quinazolines (CHEBI:6123)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inverse agonist
General Function
Virus receptor activity
Specific Function
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodop...
Gene Name
HTR2A
Uniprot ID
P28223
Uniprot Name
5-hydroxytryptamine receptor 2A
Molecular Weight
52602.58 Da
References
  1. Muntasir HA, Bhuiyan MA, Ishiguro M, Ozaki M, Nagatomo T: Inverse agonist activity of sarpogrelate, a selective 5-HT2A-receptor antagonist, at the constitutively active human 5-HT2A receptor. J Pharmacol Sci. 2006 Oct;102(2):189-95. Epub 2006 Oct 7. [PubMed:17031071]

Drug created on October 20, 2016 16:29 / Updated on August 02, 2018 06:39